It has recently been described that alternative oncogenic drivers may be found in KRAS wild-type (KRAS WT) pancreatic cancers. This study aimed to determine the incidence of targetable gene fusions present in KRAS WT pancreatic adenocarcinoma and response to targeted therapy. METHODS: One hundred consecutive patients with pancreatic adenocarcinoma who underwent targeted next-generation sequencing using DNA sequencing with RNA sequencing (n = 47) or without RNA sequencing (n = 53) at a single institution were included in the study. The frequency and landscape of targetable fusions in KRAS WT pancreatic adenocarcinoma was characterized and compared with the frequency of fusions in KRAS-mutated (KRAS MUT) pancreatic adenocarcinoma. Results were validated in two independent cohorts using data from AACR GENIE (n = 1,252) and TCGA (n = 150). The clinical history of fusion-positive patients who received targeted treatment is described. RESULTS: Pancreatic cancers from 13 of 100 patients (13%) were found to be KRAS WT. Targetable fusions were identified in 4/13 (31%) KRAS WT tumors compared with 0/87 (0%) KRAS MUT pancreatic adenocarcinomas (P = .0002). One patient with a novel MET fusion had a complete response to targeted therapy with crizotinib that is ongoing at 12+ months of treatment. In the validation cohorts, gene fusions were identified in 18/97 (19%) and 2/10 (20%) KRAS WT tumors reported in the AACR GENIE and TCGA cohorts, respectively. CONCLUSION: Oncogene fusions are present in KRAS WT pancreatic adenocarcinomas at an increased frequency when compared with KRAS MUT pancreatic adenocarcinomas. As these fusions may be susceptible to targeted therapy, molecular analyses for the detection of fusions in KRAS WT pancreatic adenocarcinomas may warrant increased consideration.
It has recently been described that alternative oncogenic drivers may be found in KRAS wild-type (KRAS WT) pancreatic cancers. This study aimed to determine the incidence of targetable gene fusions present in KRAS WT pancreatic adenocarcinoma and response to targeted therapy. METHODS: One hundred consecutive patients with pancreatic adenocarcinoma who underwent targeted next-generation sequencing using DNA sequencing with RNA sequencing (n = 47) or without RNA sequencing (n = 53) at a single institution were included in the study. The frequency and landscape of targetable fusions in KRAS WT pancreatic adenocarcinoma was characterized and compared with the frequency of fusions in KRAS-mutated (KRAS MUT) pancreatic adenocarcinoma. Results were validated in two independent cohorts using data from AACR GENIE (n = 1,252) and TCGA (n = 150). The clinical history of fusion-positive patients who received targeted treatment is described. RESULTS: Pancreatic cancers from 13 of 100 patients (13%) were found to be KRAS WT. Targetable fusions were identified in 4/13 (31%) KRAS WT tumors compared with 0/87 (0%) KRAS MUT pancreatic adenocarcinomas (P = .0002). One patient with a novel MET fusion had a complete response to targeted therapy with crizotinib that is ongoing at 12+ months of treatment. In the validation cohorts, gene fusions were identified in 18/97 (19%) and 2/10 (20%) KRAS WT tumors reported in the AACR GENIE and TCGA cohorts, respectively. CONCLUSION: Oncogene fusions are present in KRAS WT pancreatic adenocarcinomas at an increased frequency when compared with KRAS MUT pancreatic adenocarcinomas. As these fusions may be susceptible to targeted therapy, molecular analyses for the detection of fusions in KRAS WT pancreatic adenocarcinomas may warrant increased consideration.
Authors: Christopher R McEvoy; Huiling Xu; Kortnye Smith; Dariush Etemadmoghadam; Huei San Leong; David Y Choong; David J Byrne; Amir Iravani; Sophie Beck; Linda Mileshkin; Richard W Tothill; David D Bowtell; Bindi M Bates; Violeta Nastevski; Judy Browning; Anthony H Bell; Chloe Khoo; Jayesh Desai; Andrew P Fellowes; Stephen B Fox; Owen Wj Prall Journal: J Clin Invest Date: 2019-03-05 Impact factor: 14.808
Authors: Maeve A Lowery; Emmet J Jordan; Olca Basturk; Ryan N Ptashkin; Ahmet Zehir; Michael F Berger; Tanisha Leach; Brian Herbst; Gokce Askan; Hannah Maynard; Danielle Glassman; Christina Covington; Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; David S Klimstra; Jaclyn F Hechtman; David M Hyman; Peter J Allen; William R Jarnagin; Vinod P Balachandran; Anna M Varghese; Mark A Schattner; Kenneth H Yu; Leonard B Saltz; David B Solit; Christine A Iacobuzio-Donahue; Steven D Leach; Eileen M O'Reilly Journal: Clin Cancer Res Date: 2017-07-28 Impact factor: 12.531
Authors: Zishuo I Hu; Jinru Shia; Zsofia K Stadler; Anna M Varghese; Marinela Capanu; Erin Salo-Mullen; Maeve A Lowery; Luis A Diaz; Diana Mandelker; Kenneth H Yu; Alice Zervoudakis; David P Kelsen; Christine A Iacobuzio-Donahue; David S Klimstra; Leonard B Saltz; Ibrahim H Sahin; Eileen M O'Reilly Journal: Clin Cancer Res Date: 2018-01-24 Impact factor: 12.531
Authors: Andrew J Aguirre; Jonathan A Nowak; Nicholas D Camarda; Richard A Moffitt; Arezou A Ghazani; Mehlika Hazar-Rethinam; Srivatsan Raghavan; Jaegil Kim; Lauren K Brais; Dorisanne Ragon; Marisa W Welch; Emma Reilly; Devin McCabe; Lori Marini; Kristin Anderka; Karla Helvie; Nelly Oliver; Ana Babic; Annacarolina Da Silva; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Joseph P St Pierre; Kelly P Burke; Thomas Clancy; James M Cleary; Leona A Doyle; Kunal Jajoo; Nadine J McCleary; Jeffrey A Meyerhardt; Janet E Murphy; Kimmie Ng; Anuj K Patel; Kimberly Perez; Michael H Rosenthal; Douglas A Rubinson; Marvin Ryou; Geoffrey I Shapiro; Ewa Sicinska; Stuart G Silverman; Rebecca J Nagy; Richard B Lanman; Deborah Knoerzer; Dean J Welsch; Matthew B Yurgelun; Charles S Fuchs; Levi A Garraway; Gad Getz; Jason L Hornick; Bruce E Johnson; Matthew H Kulke; Robert J Mayer; Jeffrey W Miller; Paul B Shyn; David A Tuveson; Nikhil Wagle; Jen Jen Yeh; William C Hahn; Ryan B Corcoran; Scott L Carter; Brian M Wolpin Journal: Cancer Discov Date: 2018-06-14 Impact factor: 39.397
Authors: R Dienstmann; J Rodon; A Prat; J Perez-Garcia; B Adamo; E Felip; J Cortes; A J Iafrate; P Nuciforo; J Tabernero Journal: Ann Oncol Date: 2013-11-20 Impact factor: 32.976
Authors: Junji Tsurutani; Hiroji Iwata; Ian Krop; Pasi A Jänne; Toshihiko Doi; Shunji Takahashi; Haeseong Park; Charles Redfern; Kenji Tamura; Trisha M Wise-Draper; Kaku Saito; Masahiro Sugihara; Jasmeet Singh; Takahiro Jikoh; Gilles Gallant; Bob T Li Journal: Cancer Discov Date: 2020-03-25 Impact factor: 39.397
Authors: Philip A Philip; Ibrahim Azar; Joanne Xiu; Michael J Hall; Andrew Eugene Hendifar; Emil Lou; Jimmy J Hwang; Jun Gong; Rebecca Feldman; Michelle Ellis; Phil Stafford; David Spetzler; Moh'd M Khushman; Davendra Sohal; A Craig Lockhart; Benjamin A Weinberg; Wafik S El-Deiry; John Marshall; Anthony F Shields; W Michael Korn Journal: Clin Cancer Res Date: 2022-06-13 Impact factor: 13.801
Authors: James T Topham; Erica S Tsang; Joanna M Karasinska; David F Schaeffer; Daniel J Renouf; Andrew Metcalfe; Hassan Ali; Steve E Kalloger; Veronika Csizmok; Laura M Williamson; Emma Titmuss; Karina Nielsen; Gian Luca Negri; Sandra E Spencer Miko; Gun Ho Jang; Robert E Denroche; Hui-Li Wong; Grainne M O'Kane; Richard A Moore; Andrew J Mungall; Jonathan M Loree; Faiyaz Notta; Julie M Wilson; Oliver F Bathe; Patricia A Tang; Rachel Goodwin; Gregg B Morin; Jennifer J Knox; Steven Gallinger; Janessa Laskin; Marco A Marra; Steven J M Jones Journal: Nat Commun Date: 2022-10-08 Impact factor: 17.694